☆ 4.6 Letter

Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection
Article Immunology

Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease

Bjorn Kantso et al.

VACCINE (2015)

Add to Collection
Article Gastroenterology & Hepatology

Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine

Chang Kyun Lee et al.

JOURNAL OF CROHNS & COLITIS (2014)

Add to Collection
Article Gastroenterology & Hepatology

Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine

Chang Kyun Lee et al.

JOURNAL OF CROHNS & COLITIS (2014)

Add to Collection
Article Gastroenterology & Hepatology

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study

Gionata Fiorino et al.

INFLAMMATORY BOWEL DISEASES (2012)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.